- Home
- CASI vs CTXR Comparison
CASI vs CTXR Comparison
Compare CASI & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- CTXR
- Stock Information
- Founded
- CASI 1991
- CTXR 2007
- Country
- CASI China
- CTXR United States
- Employees
- CASI N/A
- CTXR N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- CTXR Health Care
- Exchange
- CASI Nasdaq
- CTXR Nasdaq
- Market Cap
- CASI 20.5M
- CTXR 18.7M
- IPO Year
- CASI 1996
- CTXR N/A
- Fundamental
- Price
- CASI $2.36
- CTXR $1.35
- Analyst Decision
- CASI Strong Buy
- CTXR Strong Buy
- Analyst Count
- CASI 1
- CTXR 3
- Target Price
- CASI $4.00
- CTXR $53.00
- AVG Volume (30 Days)
- CASI 3.7M
- CTXR 360.0K
- Earning Date
- CASI 09-02-2025
- CTXR 08-12-2025
- Dividend Yield
- CASI N/A
- CTXR N/A
- EPS Growth
- CASI N/A
- CTXR N/A
- EPS
- CASI N/A
- CTXR N/A
- Revenue
- CASI $31,368,000.00
- CTXR N/A
- Revenue This Year
- CASI N/A
- CTXR N/A
- Revenue Next Year
- CASI N/A
- CTXR $851.67
- P/E Ratio
- CASI N/A
- CTXR N/A
- Revenue Growth
- CASI 8.39
- CTXR N/A
- 52 Week Low
- CASI $1.09
- CTXR $0.65
- 52 Week High
- CASI $7.67
- CTXR $17.00
- Technical
- Relative Strength Index (RSI)
- CASI 64.70
- CTXR 49.89
- Support Level
- CASI $1.95
- CTXR $1.18
- Resistance Level
- CASI $3.09
- CTXR $1.45
- Average True Range (ATR)
- CASI 0.34
- CTXR 0.10
- MACD
- CASI 0.07
- CTXR -0.00
- Stochastic Oscillator
- CASI 55.21
- CTXR 62.96
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.